• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antiplatelet treatment in stroke: new insights.
CONCLUSIONS: Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke or transient ischemic attack. Moreover, clinicians should carefully assess the pros and cons in each case and individualize the need for prolonged dual antiplatelet therapy. PMID: 27291399 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 8, 2016 Category: Drugs & Pharmacology Authors: Milionis H, Liontos A, Vemmos K, Spengos K Tags: Curr Pharm Des Source Type: research

WITHDRAWN: Chuanxiong preparations for preventing stroke.
CONCLUSIONS: Nao-an capsule may be a choice for the primary prevention of stroke. However, the design of the study providing this evidence means that there was potential for results to have been affected by bias from the way participants may have been selected, or from investigators' conflicts of interests. There was a lack of description of the methodology in the two other studies therefore evidence from these was considered too weak to draw any firm conclusions. Further high quality research is required. PMID: 27258581 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - June 2, 2016 Category: Journals (General) Authors: Yang X, Zeng X, Wu T Tags: Cochrane Database Syst Rev Source Type: research

Taking aspirin quickly after minor stroke 'can cut risk of recurrence'
Urgent treatment with blood-thinning drug greatly reduces risk of subsequent fatal or disabling stroke, research findsDeath and disability can be averted by quickly taking aspirin after a minor stroke, a study has found. The blood-thinning drug is already given to people who have suffered a transient ischaemic attack (TIA), or “mini-stroke”, after they have been assessed in hospital. Continue reading...
Source: Guardian Unlimited Science - May 19, 2016 Category: Science Authors: Press Association Tags: Medical research Aspirin UK news Science Health Source Type: news

Sodium Sulfide, a Hydrogen Sulfide-Releasing Molecule, Attenuates Acute Cerebral Ischemia in Rats.
CONCLUSION: Sodium sulfide, a H2 S donor, presents protective effect on acute cerebral ischemia, and might be a promising therapeutic drug. PMID: 27160344 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - May 8, 2016 Category: Neuroscience Authors: Shi HQ, Zhang Y, Cheng MH, Fan BS, Tian JS, Yu JG, Chen B Tags: CNS Neurosci Ther Source Type: research

An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes
Myocardial infarction and stroke are two of the leading causes of death and disability worldwide [1,2]. Using a combination of aspirin and a platelet P2Y12 antagonist, several large clinical trials have definitively demonstrated the efficacy of dual antiplatelet therapies in preventing myocardial infarction, stroke or death in patients with acute coronary syndromes [3–8]. Dual antiplatelet therapy with aspirin and a thienopyridine-based P2Y12 antagonist (clopidogrel or prasugrel) has now become the standard of care of patients with acute coronary syndromes.
Source: Thrombosis Research - October 16, 2015 Category: Hematology Authors: Frederick A. Ofosu Source Type: research

MRI ameliorates the prediction of further clinical evolution even months after ischemic stroke
Publication date: September 2015 Source:Annals of Physical and Rehabilitation Medicine, Volume 58, Supplement 1 Author(s): V. Quintaine, H. Chabriat, E. Jouvent, A. Yelnik Background Late recovery after a first ischemic stroke is highly variable and its predictors are unknown. The present study aims at determining whether MRI data obtained one to four months after a first ischemic stroke help to predict clinical evolution up to 2 years. Methods Patients included in the PERFORM MRI study, an ancillary study of the PERFORM randomized control trial of terutroban against aspirin in secondary prevention of vascular ische...
Source: Annals of Physical and Rehabilitation Medicine - October 2, 2015 Category: Rehabilitation Source Type: research

Dual antiplatelet therapy for TIA reduces subsequent disability: A CHANCE to improve outcomes?
In this study, they explored the outcomes of functional disability, as measured by the modified Rankin Scale, and quality of life, as measured by the EuroQol-5 Dimension. The published CHANCE trial results demonstrated that the combination of clopidogrel and aspirin (for 21 days, followed by clopidogrel alone until 90 days) was superior to aspirin plus placebo for 90 days in preventing recurrent stroke after TIA or minor stroke.2 The current study demonstrates the superiority of dual antiplatelet therapy compared to aspirin in improving the 90-day functional outcome. The analysis suggests that this is mediated via a reduct...
Source: Neurology - August 17, 2015 Category: Neurology Authors: Alderazi, Y. J. Tags: Stroke prevention, Clinical trials Methodology/study design, Infarction EDITORIALS Source Type: research

Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
DiscussionThe trial has recruited more than 50% of its target sample size (latest number: 2399) and is running in 104 sites in 4 countries. One‐third of patients presented with a transient ischemic attack.
Source: International Journal of Stroke - June 16, 2015 Category: Neurology Tags: Protocol Source Type: research

Loading doses of aspirin and clopidogrel prior to Enterprise stent-assisted repair of intracranial aneurysm-a pilot study (P3.117)
Conclusions: Loading dose of antiplatelet in Enterprise stent-assisted repair of intracranial aneurysm is not only safe and feasible but associated with good clinical outcome. Therefore, loading doses antiplatelets is an alternative option for patients who are candidates for stent-assisted repair of intracranial aneurysm.Disclosure: Dr. Lodi has nothing to disclose. Dr. Reddy has nothing to disclose. Dr. Devasenapathy has nothing to disclose. Dr. Shehadeh has nothing to disclose. Dr. Hourini has nothing to disclose. Dr. Chou has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Lodi, Y., Reddy, V., Devasenapathy, A., Shehadeh, K., Hourini, A., Chou, C.-A. Tags: Cerebrovascular Disease and Interventional Neurology: Subarachnoid Hemorrhage and Miscellany Source Type: research

Overcoming Framing Bias in Stroke Neurologists' Assessments of the Minimally Clinically Important Difference for Novel Acute Ischemic Stroke Therapies (P4.187)
CONCLUSIONS: When assessed with framing based on clinical practice rather than convenience, vascular neurologists indicated the MCID for a safe agent to be worthwhile to use in acute ischemic stroke is about 1[percnt]. Drug and device agencies should consider this value to be the expert opinion MCID for acute ischemic stroke treatments when making regulatory decisions.Disclosure: Dr. Cranston has nothing to disclose. Dr. Kaplan has nothing to disclose. Dr. Saver has received personal compensation for activities with the University of California, BrainsGate, CoAxia, eV3, Talecris Biotherapeutics Inc., and PhotoThera, Inc.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Cranston, J., Kaplan, B., Saver, J. Tags: Research Methodology and Education Source Type: research

The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders
Cardiovascular disease (CVD) includes a number of conditions such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism. CVD is a leading health problem worldwide and a major cause of mortality, morbidity, and disability; it is also associated with high healthcare costs. The incidence of CVD is predicted to increase in the forthcoming years, and thus it is crucial that physicians are aware of the benefits and limitations of the available therapies to ensure patients receive optimized treatment.
Source: Thrombosis Research - December 12, 2014 Category: Hematology Authors: A.T. Cohen, S. Imfeld, J. Markham, S. Granziera Tags: Review Article Source Type: research

P-008 Loading Doses of Aspirin and Clopidogrel Prior to Enterprise Stent-assisted Repair of Intracranial Aneurysm-A Single Center Experience
Conclusions Using loading doses of aspirin and clopidogrel in Enterprise stent-assisted repair of intracranial aneurysm is not only safe and feasible but associated with good clinical outcome. Therefore, loading doses of aspirin and clopidogrel is an alternative option for patients who are candidates for stent-assisted repair of intracranial aneurysm. Disclosures Y. Lodi: None. V. Reddy: None. A. Devasenapathy: None. J. Chou: None. K. Shehades: None. K. Sethi: None. D. Galyon: None. S. Bajwa: None.
Source: Journal of NeuroInterventional Surgery - July 26, 2014 Category: Neurosurgery Authors: Lodi, Y., Reddy, V., Devasenapathy, A., Chou, J., Shehades, K., Sethi, K., Galyon, D., Bajwa, S. Tags: Oral poster abstracts Source Type: research

GPs to review aspirin use in atrial fibrillation patients
NICE calls for increased uptake of anticoagulantsRelated items from OnMedicaAlteplase use linked to reduction in disability after strokeGPs should screen over 65s for atrial fibrillationAtrial fibrillation raises risk of cognitive problems Statin use after stroke not linked to bleedsNew guidance to prevent strokes
Source: OnMedica Latest News - June 19, 2014 Category: UK Health Source Type: news

Million hearts: prevalence of leading cardiovascular disease risk factors - United States, 2005-2012.
Abstract Each year, approximately 1.5 million U.S. adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability. Overall, an estimated 14 million survivors of heart attacks and strokes are living in the United States. In 2011, the U.S. Department of Health and Human Services, in collaboration with nonprofit and private organizations, launched Million Hearts (http://www.millionhearts.hhs.gov), an initiative focused on implementing clinical and community-level evidence-based strategies to reduce cardiovascular disease (CVD) risk...
Source: MMWR Morb Mortal Wkl... - May 30, 2014 Category: Epidemiology Authors: Ritchey MD, Wall HK, Gillespie C, George MG, Jamal A, Division for Heart Disease and Stroke Prevention, CDC Tags: MMWR Morb Mortal Wkly Rep Source Type: research

Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
CONCLUSIONS: The available trial evidence showed that, for individuals with acute ischaemic stroke, GP IIb-IIIa inhibitors are associated with a significant risk of intracranial haemorrhage with no evidence of any reduction in death or disability in survivors. These data do not support their routine use in clinical practice. The conclusion is driven by trials of Abciximab, which contributed 89% of the total number of study participants considered. PMID: 24609741 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 8, 2014 Category: Journals (General) Authors: Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I Tags: Cochrane Database Syst Rev Source Type: research

Pages: 1  2  3  4  5